fda compounding glp-1 warning letters october 2025 New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages FDA issued 25 warning letters

GLP-1 receptor agonists are not diuretics, and increased urination is not a recognised adverse reaction in UK product information

The first is a resolution of NASH or steatohepatitis, and the second is an improvement of fibrosis stage

Such complexity demands exceptional precision and reproducibility to ensure consistent particle size, ligand density, encapsulation efficiency, and ultimately, therapeutic efficacy and safety

And that number appears to be rising as drug makers develop new versions, including oral medicines in place of injections and products approved for different diseases

What are GLP-1 drugsand why do they affect alcohol